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Abstract
Background: Norfloxacin like other fluoroquinolones, is known to be mutagenic for Salmonella
typhimurium TA102 strain. This mutagenic effect is due to free oxygen radicals (ROS), because it is
inhibited by antioxidants such as β-carotene and naturally occurring antioxidants of Roheo discolor
and other plants. The aim of this work was to evaluate combination therapy with norfloxacin and
vitamins C and E, to reduce the possible genotoxic risk associated with fluoroquinolones.
Method: The antimutagenicity of α-tocoferol (Vitamin E) and ascorbic acid (Vitamin C) against
norfloxacin-induced mutation was evaluated on S. typhimurium TA102, using the aroclor-1254-
induced S9 rat liver homogenate. The minimum inhibitory concentration (MIC) a measure of the
bactericidal effect of norfloxacin, was obtained in vitro by the plate dilution method.
Results: Vitamin E (0.5 mg per Petri dish) induced a statistically significant reduction (P < 0.001)
in the mutagenicity of norfloxacin, whereas Vitamin C (1 mg per Petri dish) had no such effect.
Neither of these vitamins altered the MIC for norfloxacin against 25 uropathogenic strains of
Escherichia coli.
Conclusion:  These results suggest that Vitamin E is a potent antimutagen that would be
worthwhile being used in conjunction with fluoroquinolone treatment. The minimal antimutagenic
effect of Vitamin C observed under these experimental conditions may have been because Vitamin
C in the Ames test induces a Fenton reaction, and if divalent cations are present, it can act as a pro-
oxidant rather than an antioxidant. Ascorbic acid should be further evaluated in the presence of
different divalent cations concentrations.
Background
Fluoroquinolones were first introduced in the late 1970s,
and since then, they have been successfully used as thera-
peutic agents. These antibiotics have a wide bactericidal
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spectrum against Gram-negative and Gram-positive bacte-
ria, anaerobic bacteria, and even Mycobacterium. They have
useful pharmacokinetic properties, achieve high tissue
and serum levels, and have chemical and biological stabil-
ity. Several fluoroquinolones have been developed, and
many derivates have been synthesized to improve bacteri-
cidal and metabolic properties. Unfortunately, these
structural changes have resulted in an increase in toxic and
genotoxic effects [1].
Norfloxacin is one of the most frequently employed fluo-
roquinolones against urinary infections, pyelitis, cysto-
pyelitis, epididymitis, prostatitis, pharyngitis caused by β-
lactamase resistant bacteria, and gastric infections. Never-
theless, it has been reported that fluoroquinolones are
photomutages that are able to absorb UV light with a
potential energy or electron transfer, which can induce
DNA damage [2]. Other studies have shown that less bac-
tericidal doses of norfloxacin induce mutations in S. typh-
imurium  TA102 and TA104 strains, but do not induce
genotoxic mutations in the E. coli Pol A-/PolA+ system [3].
Fluoroquinolone-induced oxidative damage may be
inhibited by antioxidant compounds. In several short gen-
otoxic test systems, Krizkova et al [4]. have inhibited
ofloxacin mutagenesis of Euglena gracilis, by using phe-
nolic compounds like caffeic acid and ferulic acid. The
oxidative DNA damage in S. thyphimurium TA1O2
induced by norfloxacin is inhibited by β-carotene metab-
olites or naturally occurring extracts from plants such as
Roheo discolor [4,5]. These data provide evidence that nor-
floxacin is an ROS-generating drug. ROS are known to be
a major cause of cancer, aging and many other degenera-
tive diseases. Therefore, it is advisable to avoid or reduce
their use, or to propose alternative DNA-damage reduc-
tion methods [6].
On the other hand, fluoroquinolones, such as nor-
floxacin, are extremely useful therapeutic drugs, whose
use cannot be avoided, despite them being ROS genera-
tors, if a risk-benefit analysis is carefully done. Consump-
tion of a diet rich in antioxidants, such as vitamins, which
are required as micronutrients in the human diet, is per-
haps a good alternative to improve health and reduce the
risks associated with ROS exposure [7].
The purposes of this study were to evaluate combination
therapy with norfloxacin and vitamins C and E, to reduce
the possible genotoxic risk associated with fluoroquinolo-
nes.
Methods
Reagents and strains
Norfloxacin was kindly donated by Aplicaciones Farma-
céuticas, S.A. México (CAS No. 70458-96-7). This antibi-
otic was tested as a chemically pure salt, as it is used in
commercial preparations. Vitamin E (α-tocopherol ace-
tate; CAS No. 7695-91-2) was kindly donated by Produc-
tos Roche, S.A. de C.V., Mexico, D:F., México Vitamin C
(L-ascorbic acid sodium salt; CAS No. 50-81-7), ampicil-
lin, tetracycline, D-biotin, glucose 6-phosphate (G6P), β-
nicotinamide adenine dinucleotide phosphate (NADP),
mitomycin-C, 2-amino-antracene (2AA), DMSO and L-
histidine were purchased from Sigma (St. Louis, MO,
USA). Aroclor 1254-induced rat liver homogenate was
prepared as described by Maron and Ames [8]. Dr. B.N.
Ames, University of California (Berkeley, CA, USA) kindly
donated S. typhimurium TA102. Uropathogenic strains of
E. coli were obtained from patients with symptomatic uri-
nary infections [9].
Mutagenicity assays
S. typhimurium TA102 overnight cultures were prepared on
nutrient broth (Oxoid No. 2) in a water-shaking bath at
37°C. One hundred microliters of this culture were
exposed to 7–700 ng norfloxacin per Petri dish, or to
mitomycin-C (20 ng per Petri dish) or 2AA (10 μg per
Petri dish) as positive controls, and poured into screw-top
sterile tubes. Assays were performed with 500 μl of the S9
mixture of aroclor 1254-induced rat liver homogenate.
Tubes were incubated for 60 min at 37°C and 90 rpm in
a shaking water. Two milliliters of soft agar was added as
described by Maron and Ames [8]. Then, 2.0 ml soft agar
was added, along with 0.05 mM histidine, vortexed, and
plated on Vogel Bonner plates. Histidine revertants (His+)
were counted in a Fisher colony counter after incubation
for 48 h at 37°C.
Antimutagenicity assays
Each culture was exposed to different doses of nor-
floxacin, as described above, and 100 or 1000 μg per Petri
dish of Vitamin C dissolved in distilled water. α-Tocophe-
rol acetate was mixed in ethylene glycol at 500 and 1000
μg per Petri dish. Assays were performed with 500 μl of
the S9 mixture of aroclor 1254-induced rat liver homoge-
nate, as described by Maron and Ames [8]. All tube con-
tents were treated as described above.
Statistical analysis
The means and SE were calculated using standard proce-
dures. The statistical significance of differences between
group means was evaluated by ANOVA Bonferroni test,
taking a probability of 0.05% as the criterion of signifi-
cance. All values reported are the mean ± SE.
In vitro bactericidal activity
Dilutions of norfloxacin were prepared from a stock solu-
tion containing 64 μg/ml norfloxacin in 0.01 N NaOH
(0.05–32 μg/ml). One milliliter of these solutions, with or
without vitamins were poured onto sterile Petri dishes,BMC Pharmacology 2008, 8:2 http://www.biomedcentral.com/1471-2210/8/2
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and 9.0 ml Muller-Hinton agar at 45°C was added and
gently mixed. Plates were allowed to dry at room temper-
ature overnight. Uropathogenic E. coli strains were cul-
tured on Mc Conkey agar and suspensions were adjusted
in a Mc Farland 0.5 tube and then diluted 1:10. The final
strain dilution that was deposited on a Steers replicator
was 104 cfu. Norfloxacin plates, with or without vitamins
C or E, were inoculated with microcolonies of S. thyphimu-
rium TA1O2. Controls of Muller Hinton plate were also
scored. All plates were incubated at 37°C for 18 h and the
number of resistant strains was evaluated, with or without
vitamins C or E. [10].
Results
In vitro bactericidal activity testing against 25 different
uropathogenic strains obtained from symptomatic preg-
nant women showed that 22 strains (88.0%) were sensi-
tive to norfloxacin, as it is expressed by the National
Commitee for Clinical Laboratory Standards (NCCLS)
[10]. whereas the other three (12%) isolates were resistant
to norfloxacin. The addition of vitamins C or E did not
change the observed sensitivity or resistance pattern.
The observed mutagenicity of norfloxacin on S. typhimu-
rium  TA102 was similar to that reported previously,
employing the preincubation Ames test with Aroclor
1254-induced rat liver homogenate [10]. This mutagenic
effect was significantly reduced (p < 0.001) by Vitamin C
from 2457 ± 181 to 1967 ± 79 His+ Revertans for 100 μg
when 7 ng of norfloxacine was utilized, the same effect
was obtained with 1000 μg of Vitamin C as shown in Fig.
1. Vitamin E (500 μg per Petri dish) induced a significant
reduction (P < 0.001) of the induced revertants (Fig. 2)
Discussion
Fluoroquinolone antibiotics present a good therapeutic
option for several infectious diseases [1]. Therefore,
despite the fact that fluoroquinolones are oxygen free rad-
ical generators and are photo-genotoxic chemicals; it is
not advisable to avoid their use. Antimutagens are a good
alternative for reducing the genotoxic risk of fluoroqui-
nolones. Some natural compounds, such as caffeic, genti-
sic and ferulic acids, have been shown to act as scavengers
of reactive oxygen species (ROS) induced by the fluoro-
quinolone ofloxacin [11]. Meanwhile, the use of vitamins
is strongly advised with prescribed antibiotics, to reduce
DNA damage, as long as they do not reduce the bacteri-
cidal potency of the antibiotics [7]. Vitamin C, 80 mg
daily (1 mg/dl) is essential for an adequate interaction
between tissues and folate metabolism, and is essential
for prevention of scurvy. Vitamin E is the most important
hydrophobic antioxidant, protecting biological molecules
like DNA, proteins and lipids against ROS, with a useful
dose of 10 mg daily (4–20 mg/dl) [12].
In the present study, less than the recommended daily
dose (100 μg) of the vitamins was evaluated because of
the hydrophobic properties of the vitamins. Vitamin E
was shown to be a potent antimutagen against mutation
Antioxidant effect of Vitamin E as an inhibitor of mutagenesis  induced by norfloxacin in S. typhimurium TA102 Figure 2
Antioxidant effect of Vitamin E as an inhibitor of mutagenesis 
induced by norfloxacin in S. typhimurium TA102. Data are the 
mean ± SE (n = 9) * p < 0.001 vs control of each group of 
norfloxanin concentration. The antimutagenic effect of vita-
min E at 1000 μg/Petri utilizing 7.0 ng/norfloxacin, was signifi-
cantly (1997 ± 36 to 911 ± 38 His+ Revertants). The value is 
54.4% lesser than the control.
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Antimutagenesis of vitamin C against mutation induced by  norfloxacin in S. typhimurium TA102 Figure 1
Antimutagenesis of vitamin C against mutation induced by 
norfloxacin in S. typhimurium TA102. Data are the mean ± SE 
(n = 9) * p < 0.01 vs control of each group ofnorfloxanin con-
centration. The antimutagenic effect of vitamin C at 1000 μg/
Petri dish, was significantly (2457 ± 181 to 2070 ± 86 His+ 
Revertants) utilizing 7.0 ng/norfloxacin. The value is 16.74% 
lesser than the control.
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induced by norfloxacin, because of its antioxidant proper-
ties. In fact, 500 μg of vitamin E was able to reduce the
mutagenicity of norfloxacin. This result is in accordance
with those of Drisko et al [13], who have recommended
the use of Vitamin E to increase the safety and efficacy of
chemotherapy in ovarian cancer, and the results of Ames
[7], who have suggested the use of vitamin B6 as an alter-
native to reduce radiation risk. Our results also show that
vitamin E or C did not interfere with the MIC of nor-
floxacin against uropathogenic strains of E. coli. This may
be because the DNA gyrase inhibition of norfloxacin is
not dependent on ROS generation for its mutagenic effect,
which can be inhibited by antioxidants [4].
The advantage of Vitamin C use as an antimutagen and
antioxidant has been extensively studied in vitro and in
vivo, and it has been shown to decrease chromosomal
damage in vivo [14]. The recommended serum concentra-
tion of 1 mg of vitamin C did not significantly reduce the
mutagenicity of norfloxacin. This result might be
explained by the presence of cations in the distillated
water, and the addition of Mg2+ and Ca2+ to the Cyp-450
(cytochrome P450) aroclor induced rat liver S9 mixture
might induce a Fenton reaction [15]. Other studies, in
accordance with our own, have also reported that Vitamin
C, under the Ames test conditions, is not a good antioxi-
dant against other potent mutagens, including fluoroqui-
nolones such as nitrofurans and furazolidone. The
antioxidant capacity of AA against fluoroquinolones
might be evaluated under different physiological condi-
tions, to establish its ability to reduce mutagenesis
induced by these drugs.
Vitamins C or E did not modify the MIC patterns of nor-
floxacin against uropathogenic strains. Therefore, the
simultaneous use of these vitamins with fluoroquinolone
therapy is advisable to reduce the genotoxic risk of ROS
generated by norfloxacin. Other studies have reported that
antioxidants are able to reduce the development of antibi-
otic resistance among pathogenic bacteria, because oxy-
gen free radicals generated by antibiotic metabolism may
also be a major cause of antibiotic resistance development
[16].
Conclusion
In conclusion, our results suggest that the studied vita-
mins due their potent antioxidant capacities that reduce
norfloxacin-induced mutagenesis. As they do not interfere
with the bactericidal activity of the antibiotics, they might
by a good alternative to reduce genotoxic risk associated
with norfloxacin therapy.
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